Nanovesicular transdermal delivery patches have previously had success: A beginning step toward a giant leap in drug delivery

Kadae Eediga Sailaja[1*], Bhupalam Pradeepkumar[2]

[1] Research Scholar, Department of Pharmaceutical Sciences, Jawaharlal Nehru Technological Journal, Anantapur, Ananthapuramu-515001, Andhra Pradesh, India.

[2]Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, K. R. Palli Cross, Ananthapuramu-515721, Affiliated to Jawaharlal Nehru Technological Journal, Anantapur, Ananthapuramu-515001, Andhra Pradesh, India

Correspondence: charansailajaotpri@gmail.com

Abstract: Without a doubt, nanoformulations are extremely useful tools for applications involving medication delivery. Watching the initial notions and ideas evolve during this current "golden age" of pharmacological nanocarriers. When optimising and ensuring the safety and effectiveness of these systems, prior successful initiatives must be taken into consideration before the process of choosing the potatoes can begin. Nano vesicular systems have become popular because they are commonly perceived as non-toxic, biocompatible, and easy-to-produce formulations. At the outset of this review, a summary of the numerous nano vesicular transdermal systems and successful attempts are given. The authors have had some success in the past in creating various nano vesicular systems for transdermal medication delivery.

Keywords: Delivery, Drug, Literature, Nano vesicles, Polymer, Transdermal.

1. Introduction

It has been demonstrated that localised topical therapy is more successful with the SLN method than transdermal systemic delivery[1]. These carriers also have low drug loading, spill medication during storage, and have high water content in SLN dispersions. Though there was a long lag time, the developed approach demonstrated higher bioavailability[2].

Transfersomes are lipid-based vesicle carriers that can heritably traverse the skin to improve transdermal distribution[3,4]. They are self-optimizing, ultra-adaptive, and boundary activators[5]. According to several investigations, when used on an open biological barrier under non-occlusive circumstances, it is effective at penetrating intact skin and delivering medications at therapeutic quantities[6]. The highly flexible lipid bilayer vesicle system in the liquid state, which enables them to easily pass even extremely small strictures under the influence of gradients of hydration, is a crucial element involved in improving penetration through the skin via transfersomes. The vesicle can deform without losing structural integrity thanks to the edge activator's presence[7].

Edge activators have a variety of stress-dependent modifications that reduce barriers to their transit via constrained channels and enable non-invasive drug delivery. These adaptations result from their capacity to aggregate at high-stress locations and curved structures. Nanoparticles (NPs) are colloidal particles having a 10-1000 nm size[8,9]. They are produced using artificial or natural polymers and are excellent for enhancing drug distribution and lowering toxicity[10]. They have become a flexible substitute for liposomes as drug carriers. NPs ability to pass through different anatomical barriers, the prolonged release of their contents, and their stability at the nanoscale scale are all necessary for their successful application in drug delivery[11]. However, the widespread use of NPs in clinical medicine has been constrained by the lack of secure, regulatory-approved polymers and their high cost[12].

Lipids have been suggested as potential substitutes for polymeric NPs to get over these drawbacks, especially for lipophilic drugs[13]. Solid lipid nanoparticles (SLNs), which are these lipid NPs, are gaining popularity among formulators all over the world. Over the past ten years, colloidal carriers known as SLNs have been created as an alternative to currently used conventional carriers (liposomes/emulsions/NPs)[14]. They belong to a brand-new class of lipid emulsions with a sub-micron size in which the oil (liquid lipid) has been swapped out for a solid lipid. SLNs are desirable for their possibility to enhance the performance of pharmaceuticals, nutraceuticals, and other materials[15]. They offer distinctive possessions viz., small size, high surface area, high drug loading, and phase interaction at interfaces.

Since they don't have any known drawbacks like %). SLNs combine the benefits of numerous colloidal transporters while avoiding their drawbacks. The solubility of the medicament in the lipid melt, the lipid matrix's structure, and the lipid matrix's polymeric state all impact the drug-loading capacity of traditional SLNs. A flawless crystal with few flaws forms when the molecules making up the lipid matrix (such as tristearin or tripalmitin) are very comparable to one another[16]. A highly ordered crystal lattice cannot hold significant amounts of the drug since integrated medicines are present in crystal defects as well as between lipid layers and fatty acid chains. As a result, larger drug loading is more sensitive when utilising more complex lipids.

2. Major types of nanovesicles

Nanostructured lipid carriers (NLC).

To get over any potential issues with SLNs, NLCs were developed[17]. It was intended to increase drug exposure while preventing drug release. Three approaches could be used to visualise this. In the first model, various fatty acids are combined to form spatially distinct lipids (such as glycerides)[18].

Larger gaps between the glyceride fatty acid chains and overall voids in the crystal result from the usage of spatially distinct lipids, which creates more room for the accommodation of visitor molecules. By combining minor volumes of liquid lipids with solid

lipids, the maximum quantity of medication loading (oils) may be attained. The name of this model is the incomplete NLC type.

Since the progressive crystallisation or change of the solid lipid is what leads to drug excretion, the creation of the 3rd type of NLC, the amorphous-type NLC, can stop this from occurring. Here, the particles are solid, but the addition of specific lipids such as octacosanol hydroxyl, hydroxyl stearate, and isopropyl myristate prevents them from crystallising upon cooling[19].

Drugs that exhibit greater solubility in oils can be solubilized in the oil and still be dwindling from deprivation by surrounding solid lipids. These NLCs are referred to as multiple-type NLCs and are similar to w/o/w emulsions in that they are a dispersion of oil in solid and lipid in water[20].

Lipid drug conjugates (LDC)

Due to dispersion effects during the manufacturing process, SLNs have a limited capacity to load hydrophilic medicines, which is a significant issue. The solid lipid matrix can only be properly integrated with very powerful, low-dose hydrophilic medicines. So-called LDC NPs with drug-loading capacities of up to 33% have been created to get around this restriction[21]. A mass of insoluble drug-lipid conjugate is first made by covalent attachment or salification (using, for example, a fatty acid). This LDC is then treated by high-pressure homogenization into a nanoparticle formulation with Tweens. These matrices may be used to target hydrophilic drugs in the brain for the handling of severe protozoal infections.

Mode of SLN making.

SLNs can be made by high shear, hot, cold, or high-speed homogenization, solvent, micro, or double emulsification, supercritical fluid, or spray drying methods[22,23].

3. SLN characterization

The SLNs were characterised by their particle size (measured by dynamic light scattering, static light scattering, Fraunhofer diffraction/acoustic methods), and zeta potential measurements (such as nuclear magnetic resonance, electron microscopy, and atomic force microscopy)[24,25]. These SLNs can be given oral, parenteral or transdermal routes

The current review explores the past attempts made using transfersomes to safely increase the bioavailability of various drugs while avoiding extensive hepatic first-pass metabolism, ensuring adequate drug retention in the skin for an extended period, and administering the drug systemically to maintain therapeutic blood levels.

The past successful attempts so far made on nano vesicular transdermal systems are illustrated in table 1.

Table 1. Past work done on Nano vesicular transdermal systems

Drug	Polymer	Method	References
Carvedilol	Tween 80	Thin film hydration (TFH)	[26]

Diclofenac sodium and ketoprofen	Cetyltrimethylammonium bromide	TFH	[27]
Glipizide	SL, chitosan, and CHL	TFH	[28]
Raloxifene-Graphene	CHL	TFH	[29]
Rizatriptan benzoate	Carbopol 934P	EI and sonication	[30]
Methotrexate	sodium carboxy methyl cellulose, and HPMC	Solvent casting technique	[31]
Celecoxib (CLB)	Hydrogenated soy phosphatidylcholine (HSPC)	TFH	[32]
Pramipexole	1-Decanoyl-2-Hydroxy-sn-3-Phosphocholine (DPC)	TFH	[33]
Econazole nitrate	SPC and CHL	REM	[34]
Tacrolimus	SL and CHL	TFH and Curvature tuned method	[35]
Pramipexole	1-Arachidonoyl-2-Hydroxy-sn-Glycero-3-Phosphocholine (APC)	TFH	[36]
Itraconazole	Carbopol 980	TFH	[37]
Chlorophenyl benzyl ether	PC	TFH	[38].
Ketoprofen	PEG 4000	TFH	[39]
Abiraterone acetate	CHL	TFH	[40]
Aceclofenac	Phosphatidylcholine (PTC)	hand shaking technique	[41]
Raloxifene	PTC	TFH	[42]
Levofloxacin	SL and CHL	TFH	[43]
Sitagliptin	SL and CHL	EI	[44]
Rivastigmine	Propylene glycol (PG) and CHL	TFH	[45]
Letrozole	Lactose	SDM	[46]
Linezolid	SL	TFH	[47]
Baclofen	SL and stearic acid	EI	[48]
Lopinavir	Phospholipid 85G	SDM	[49]
Tretinoin and 5-fluorouracil	CHL and SL	Ethanol injection (EI)	[50]

5 Fluorouracil and Tretinoin	CHL and SL	EI	[50]
Verapamil hydrochloride	SPC, Span 80, and Sephadex G-50	Modified extrusion method	[51]
Dapsone and Cloxacillin Sodium	SL and Carbopol 934	Cold method	[52]
Tamoxifen citrate	Ethyl cellulose (EC), and hydroxypropyl methylcellulose (HPMC)	solvent displacement method	[53]
Griseofulvin	SPC	TFH	[54]
Glimepiride	SL, PG, and dimethyl sulfoxide	Phase evaporation Method and melting method	[55]
Celecoxib	SL and CHL	TFH	[56]
Avanafil	SL and CHL	TFH	[57]
Itraconazole	Carbopol 934P	TFH	[58]
Clotrimazole	Soya phosphatidylcholine (SPC), Span 80, and CHL	Rotary evaporation method (REM)	[59]
Sodium Diclofenac	Scotchpak and Cotran 9720	TFH	[60]
Ketorolac tromethamine	Tween80 and Sephadex-G-10	TFH	[61]
Fluconazole	phospholipid (PL 90H) and cholesterol (CHL), and stearic acid.	TFH	[62]
Ketoconazole	Soya lecithin (SL)	TFH	[63]
Cyproterone acetate	Hydroxyl ethyl cellulose (HEC)	TFH	[64]
Tropicamide	Phospholipon 90	TFH	[65]

Conclusion

When compared to other kinds of nanoparticles, such as liposomes, suspensions, microemulsions, and polymeric nanoparticles, solid lipid nanoparticles are colloidal dispersions with different properties. A more adaptable drug delivery system that is chemically stable and physiologically acceptable can be created by using SLNs to gradually avoid the main problems connected with nanoparticles. Their tendency to gel seems to be the sole drawback, however nanostructured lipid carriers may provide a workaround.

Additionally, the active ingredient, or the medication, may be destroyed as a result of the heat and stress produced during the creation of the hot homogenization process. Choosing the appropriate production method is crucial. Other issues that need to be addressed include particle size, the coexistence of distinct colloidal forms, diverse morphologies, and drug ejection from the lipid matrix. The numerous tried-and-true techniques for mass producing the SLN matrix and characterising it were discussed. Thermolabile drugs, that have a poorer pharmacokinetic profile or are incompatible physicochemically can all be delivered to the target site using SLNs. SLNs can also be used to transport proteins and peptides more effectively and with less toxicity. Therefore, the addition of the therapeutic strategy using SLNs has the potential to change the course of both therapies and diagnostics.

Funding
This review received no external funding.
Acknowledgments
Nil

Conflicts of Interest
The authors declare no conflict of interest.

References

1. Mishra, V.; Bansal, K.K.; Verma, A.; Yadav, N.; Thakur, S.; Sudhakar, K.; Rosenholm, J.M.J.P. Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. **2018**, *10*, 191.
2. Paliwal, R.; Paliwal, S.R.; Kenwat, R.; Kurmi, B.D.; Sahu, M.K.J.E.o.o.t.p. Solid lipid nanoparticles: A review on recent perspectives and patents. **2020**, *30*, 179-194.
3. Ahad, H.A.; Kumar, C.S.; Ravindra, B.; Sasidhar, C.; Ramakrishna, G.; Venkatnath, L.; Gangadhar, P.; Navya, K.J.I.J.o.P.S.R.; Research. Characterization and permeation studies of Diltiazem hydrochloride-ficus reticuleta fruit mucilage Transdermal patches. **2010**, *1*, 32-37.
4. Jyothika, L.S.K.; Ahad, H.A.; Haranath, C.; Kousar, S.; Sadiya, S.H. Types of Transdermal Drug Delivery Systems: A Literature Report of the Past decade. **2022**.
5. Opatha, S.A.T.; Titapiwatanakun, V.; Chutoprapat, R.J.P. Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery. **2020**, *12*, 855.
6. Fernández-García, R.; Lalatsa, A.; Statts, L.; Bolás-Fernández, F.; Ballesteros, M.P.; Serrano, D.R.J.I.j.o.p. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale. **2020**, *573*, 118817.
7. Swetha, T.; Ahad, H.A.; Reddy, K.K.; Sekhar, A.; Sivaji, S.; Kumar, B.J.D.P.L. Formulation and in-vitro permeation studies of Ketoprofen-Ficus reticulata fruit mucilage transdermal patches. **2010**, *2*, 190-199.

8. Abdul, A.H.; Bala, A.G.; Chintaginjala, H.; Manchikanti, S.P.; Kamsali, A.K.; Dasari, R.R.D.J.I.J.o.P.S.; Nanotechnology. Equator Assessment of Nanoparticles Using the Design-Expert Software. **2020**, *13*, 4766-4772.
9. Ahad, H.A.; Chintaginjala, H.; Rahamathulla, S.; Rupasree, A.; Kumar, A.S.; Pallavi, B.P. Pathfinder Nanosponges for Drug Targeting by Factorial Design: A Glance Review. **2021**.
10. HINDUSTAN, A.A.; Kumar, C.S.; Anuradha, C.; Reddy, K.K.; CHANDRA, S.A. A Novel Mucilage from Ficus glomerata Fruits for Transdermal Patches: Taking Indomethacin as a Model Drug. **2011**.
11. Fouziya, B.; Ahad, H.A.; Charan, D.S.; Vidya, J.S.; Reddy, U.C.; Reddy, P.N.J.A.J.o.P.; Technology. Fabrication and Evaluation of Cefpodoxime Proxetil Niosomes. **2022**, *12*, 109-112.
12. Sheikholeslami, M.J.S.E.M.; Cells, S. Numerical analysis of solar energy storage within a double pipe utilizing nanoparticles for expedition of melting. **2022**, *245*, 111856.
13. Shravani, Y.; Ahad, H.A.; Haranath, C.; gari Poojitha, B.; Rahamathulla, S.; Rupasree, A.J.I.J.L.S.P.R. Past Decade Work Done On Cubosomes Using Factorial Design: A Fast Track Information for Researchers..(2021). *11*, P124-135.
14. Tenchov, R.; Bird, R.; Curtze, A.E.; Zhou, Q.J.A.n. Lipid nanoparticles– from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. **2021**, *15*, 16982-17015.
15. McClements, D.J.; Zou, L.; Zhang, R.; Salvia-Trujillo, L.; Kumosani, T.; Xiao, H.J.C.R.i.F.S.; Safety, F. Enhancing nutraceutical performance using excipient foods: Designing food structures and compositions to increase bioavailability. **2015**, *14*, 824-847.
16. Sadiq, A.A.; Rassol, A.A.J.I.J.P.P.S. Formulation and evaluation of silibinin loaded solid lipid nanoparticles for peroral use targeting lower part of gastrointestinal tract. **2014**, *6*, 55-67.
17. Naseri, N.; Valizadeh, H.; Zakeri-Milani, P.J.A.p.b. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. **2015**, *5*, 305.
18. Mura, P.; Maestrelli, F.; D'Ambrosio, M.; Luceri, C.; Cirri, M.J.P. Evaluation and comparison of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as vectors to develop hydrochlorothiazide effective and safe pediatric oral liquid formulations. **2021**, *13*, 437.
19. Pottoo, F.H.; Sharma, S.; Javed, M.N.; Barkat, M.A.; Harshita; Alam, M.S.; Naim, M.J.; Alam, O.; Ansari, M.A.; Barreto, G.E.J.D.M.R. Lipid-based nanoformulations in the treatment of neurological disorders. **2020**, *52*, 185-204.
20. Attama, A.A.; Momoh, M.A.; Builders, P.F.J.R.a.i.n.d.c.s. Lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development. **2012**, *5*, 107-140.
21. Banerjee, S.; Kundu, A.J.D.J.o.P.S. Lipid-drug conjugates: a potential nanocarrier system for oral drug delivery applications. **2018**, *26*, 65-75.

eISSN 1303-5150

22. Yadav, N.; Khatak, S.; Sara, U.S.J.I.J.A.P. Solid lipid nanoparticles-a review. **2013**, *5*, 8-18.
23. Deshmukh, A.S.J.R.J.o.P.D.F.; Technology. Solid lipid nanoparticles. **2014**, *6*, 282.
24. Duan, Y.; Dhar, A.; Patel, C.; Khimani, M.; Neogi, S.; Sharma, P.; Kumar, N.S.; Vekariya, R.L.J.R.a. A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. **2020**, *10*, 26777-26791.
25. Rajpoot, K.J.C.p.d. Solid lipid nanoparticles: a promising nanomaterial in drug delivery. **2019**, *25*, 3943-3959.
26. Maan, S.; Khar, R.K.; Mazumder, R.; Yadav, N.; Khan, U.A.J.J.o.Y.P. Fabrication and Evaluation of Controlled Release Transdermal Drug Delivery System of Carvedilol using Design Expert® Software for the Management of Hypertension. **2022**, *14*, 295.
27. Kuznetsova, D.A.; Vasilieva, E.A.; Kuznetsov, D.M.; Lenina, O.A.; Filippov, S.K.; Petrov, K.A.; Zakharova, L.Y.; Sinyashin, O.G.J.A.o. Enhancement of the Transdermal Delivery of Nonsteroidal Anti-inflammatory Drugs Using Liposomes Containing Cationic Surfactants. **2022**, *7*, 25741-25750.
28. Kalpanadevi, M. Formulation and Evaluation of Proniosomal Transdermal Patches of Glipizide. Nandha College of Pharmacy, Erode, 2012.
29. Altyar, A.E.; Fahmy, O.J.D.-R. Preparation of Liposomal Raloxifene-Graphene Nanosheet and Evaluation of Its In Vitro Anticancer Effects. **2022**, *20*, 15593258211063983.
30. Kempwade, A.; Taranalli, A.; Hiremath, R.; Joshi, S.J.I.J.o.P.S. Formulation and Evaluation of Flexible Liposome Embedded In Situ Thermoreversible Intranasal Gel of Rizatriptan Benzoate. **2022**, *84*, 863-873.
31. Latif, M.S.; Al-Harbi, F.F.; Nawaz, A.; Rashid, S.A.; Farid, A.; Mohaini, M.A.; Alsalman, A.J.; Hawaj, M.A.A.; Alhashem, Y.N.J.P. Formulation and Evaluation of Hydrophilic Polymer Based Methotrexate Patches: In Vitro and In Vivo Characterization. **2022**, *14*, 1310.
32. Begum, M.Y.; M. Osmani, R.A.; Alqahtani, A.; Ghazwani, M.; Hani, U.; Ather, H.; Atiya, A.; Rahamathulla, M.; Siddiqua, A.J.P.o. Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation. **2022**, *17*, e0264518.
33. Trivedi, R.; Umekar, M.; Kotagale, N.; Bonde, S.; Taksande, J.J.J.o.d.d.s.; technology. Design, evaluation and in vivo pharmacokinetic study of a cationic flexible liposomes for enhanced transdermal delivery of pramipexole. **2021**, *61*, 102313.
34. Maharaj, S.K.; Sharma, R.; Rathi, J.C. formulation, development and evaluation of liposomal gel for treatment of fungal infection. **2021**.
35. Jindal, S.; Awasthi, R.; Singare, D.; Kulkarni, G.T.J.J.o.R.i.P. Preparation and in vitro evaluation of Tacrolimus loaded liposomal vesicles by two methods: A comparative study. **2021**, *25*, 34-41.
36. Mayangsari, F.; Surini, S.; Iswandana, R.J.J.o.A.P.S. Development of transfersomal emulgel to enhance the permeation of berberine chloride for transdermal delivery. **2022**, *12*, 048-055.

eISSN 1303-5150

37. Kumar, N.; Goindi, S.J.J.o.D.D.S.; Technology. Development, characterization and preclinical evaluation of nanosized liposomes of itraconazole for topical application: 32 full factorial design to estimate the relationship between formulation components. **2021**, *66*, 102785.
38. Singpanna, K.; Dechsri, K.; Patrojanasophon, P.; Limpachayaporn, P.; Opanasopit, P.; Nuntharatanapong, N.J.J.o.D.D.S.; Technology. Transdermal delivery, cytotoxicity and anti-melanogenic activity of p-chlorophenyl benzyl ether loaded-liposomes. **2021**, *65*, 102746.
39. Thomas, J.A.; Abraham, S.; Raju, S.P.; Das, C.; Abraham, A.; Varghese, S.A.; Abraham, E.J.R.J.o.P.; Technology. Formulation and Evaluation of Anti-Arthritis Drug Loaded Stealth Liposomes. **2021**, *14*, 1313-1318.
40. Das, S.; Samanta, A.; Mondal, S.; Roy, D.; Nayak, A.K.J.S.I. Design and release kinetics of liposomes containing abiraterone acetate for treatment of prostate cancer. **2021**, *2*, 100077.
41. Sasikala, A.; Tarakeswari, V.J.J.P.A.R. Anti-Inflammatory Flexible Liposomal Gel for Treatment of Rheumatoid Arthritis. **2021**, *4*, 1334-1345.
42. Mahmood, S.; Chatterjee, B.; Mandal, U.K.J.J.o.D.D.S.; Technology. Pharmacokinetic evaluation of the synergistic effect of raloxifene loaded transfersomes for transdermal delivery. **2021**, *63*, 102545.
43. Joseph, A.E.; Abraham, S.; Raju, S.P.; Pillai, H.H.; Jose, F.; Abraham, E.J.R.J.o.P.; Technology. Formulation and Evaluation of levofloxacin stealth liposome using different polymers. **2021**, *14*, 1493-1498.
44. Sharma, D.; Raj, S.; Singhal, M.; Kumar, B.J.N.; Nanotechnology-Asia. Preparation and Evaluation of Gliptin Liposomes for Targetting Ocular Region in Neurodegeneration. **2021**, *11*, 197-203.
45. Salimi, A.; Ghobadian, H.; Sharif Makhmalzadeh, B.J.J.o.L.R. Dermal pharmacokinetics of rivastigmine-loaded liposomes: an ex vivo–in vivo correlation study. **2021**, *31*, 246-254.
46. Maniyar, M.; Chakraborty, A.; Kokare, C.J.J.o.L.R. Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. **2020**, *30*, 274-284.
47. Golhar, A.R.; Ghume, V.K.; Merekar, D.A.N.; Dokhe, M.D.; Patil, D.B. formulation and evaluation of liposomal topical gel of linezolid for the treatment of skin infection. **2020**.
48. Keservani, R.K.; Prakash Gautam, S. Formulation and evaluation of baclofen liposome vesicles using lecithin. **2020**.
49. Maniyar, M.G.; Kokare, C.R.J.J.o.P.I. Formulation and evaluation of spray dried liposomes of lopinavir for topical application. **2019**, *49*, 259-270.
50. Tiwari, R.; Tiwari, G.; Wal, A.; Gupta, C.J.A.P. Liposomal delivery of 5 Fluorouracil and Tretinoin: An Aspect of Topical treatment of skin warts. **2019**, *60*, 139-146.

eISSN 1303-5150

51. JAIN, N.; Argal, A.; Gautam, G.J.J.o.D.D.; Therapeutics. Elastic liposomes mediated transdermal delivery of verapamil hydrochloride. **2018**, *8*, 16-21.
52. Tiwari, R.; Tiwari, G.; Wal, P.; Wal, A.; Maurya, P.J.T.O.N.J. Development, characterization and transdermal delivery of dapsone and an antibiotic entrapped in ethanolic liposomal gel for the treatment of lapromatous leprosy. **2018**, *5*.
53. Adhyapak, A.A.; Desai, B.G.J.I.J.o.H.S.; Research, B. Formulation and evaluation of liposomal transdermal patch for targeted drug delivery of tamoxifen citrate for breast cancer. **2016**, *9*, 40.
54. Bavarsad, N.; Kouchak, M.; Mohamadipour, P.; Sadeghi-Nejad, B.J.J.o.a.p.t.; research. Preparation and physicochemical characterization of topical chitosan-based film containing griseofulvin-loaded liposomes. **2016**, *7*, 91.
55. Ahmed, O.A.A.; Kurakula, M.; Banjar, Z.M.; Afouna, M.I.; Zidan, A.S.J.J.o.P.S. Quality by design coupled with near infrared in formulation of transdermal glimepiride liposomal films. **2015**, *104*, 2062-2075.
56. Moghimipour, E.; Salami, A.; Monjezi, M.J.J.j.o.n.p.p. Formulation and evaluation of liposomes for transdermal delivery of celecoxib. **2015**, *10*.
57. Hosny, K.M.; Aldawsari, H.M.J.T.J.o.P.R. Avanafil liposomes as transdermal drug delivery for erectile dysfunction treatment: Preparation, characterization, and in vitro, ex vivo and in vivo studies. **2015**, *14*, 559-565.
58. Sunitha, S.; Thirupathi, A.; Vijaya, K.J.J.p.S.I.; 25. Preparation and evaluation of liposome entrapped hydrogel complex system of itraconazole for enhanced transdermal permeation. **2014**, *29*.
59. Kumar, R.; Rana, A.; Bala, R.; Seth, N.J.I.J.o.D.D.; Research. Formulation and evaluation of elastic liposomes of clotrimazole. **2012**, *4*, 0-0.
60. Taghizadeh, S.M.; Bajgholi, S.J.J.o.B.; Nanobiotechnology. A new liposomal-drug-in-adhesive patch for transdermal delivery of sodium diclofenac. **2011**, *2*, 576.
61. Nava, G.; Piñón, E.; Mendoza, L.; Mendoza, N.; Quintanar, D.; Ganem, A.J.P. Formulation and in vitro, ex vivo and in vivo evaluation of elastic liposomes for transdermal delivery of ketorolac tromethamine. **2011**, *3*, 954-970.
62. Mitkari, B.; Korde, S.; Mahadik, K.; Kokare, C.J.I.J.P.E.R. Formulation and evaluation of topical liposomal gel for fluconazole. **2010**, *44*, 324-333.
63. Patel, R.P.; Patel, H.; Baria, A.H.J.I.J.D.D.T. Formulation and evaluation of liposomes of ketoconazole. **2009**, *1*, 16-23.
64. MOHAMMADI, S.S.; Montaseri, H.; Jamshidnejad, M. Preparation and evaluation of cyproterone acetate liposome for topical drug delivery. **2009**.
65. Nagarsenker, M.; Londhe, V.Y.; Nadkarni, G.J.I.j.o.p. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. **1999**, *190*, 63-71.

eISSN 1303-5150